Changchun ProteLight Pharmaceutical & Biotechnology Co., Ltd. was founded as research and development company.

Established Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.(ProteLight Pharma)

ProteLight Pharma officially acquired Changchun ProteLight as a wholly-owned R&D subsidiary

The antimicrobial peptide PL-5 spray project was selected into the national “12th Five-Year Plan” Mega-Projects for Innovative Drugs of China

Selected as "2014 China's Most Potential Seed Enterprises" by Ernst & Young

The antimicrobial peptide PL-5 spray obtained clinical approval for a new drug, becoming the first innovative antimicrobial peptide drug to enter human clinical trials in China

Two national category I innovative drugs, the antimicrobial peptide PL-5 spray project and the antimicrobial peptide PL-18 suppository project were selected into the "13th Five-Year Plan" major new drug innovative manufacture projects of the National Health Commission

ProteLight Pharma Industry Base forally opens
Honored as "Potential Unicorn Enterprise of Sunan National Innovation Park "
Honored as “Wuxin Prospective Unicorn Enterprise”

Established Nanjing Denovo Pharmaceutical Co., Ltd. (a wholly-owned R&D subsidiary)
Established Jiangsu Putai Pharmaceutical Technology Co., Ltd.(a wholly-owned subsidiary of disinfection products)

Established ProteLight Medical Holdings (Hong Kong) Co., Ltd. (a wholly-owned subsidiary of overseas business)

Antimicrobial Peptide PL-5 Spray Received FDA Approval for Phase II Clinical Trials in the United States
Antimicrobial Peptide PL-18 Suppository Received TGA Approval of its First Human Clinical Study in Australia